All In Biotech

Drug Trial Radar · NCT07914088

A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis

A Phase II Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of AR100DP1 in Subjects With Mild to Moderate Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Arjil Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is composed of a two-arm, double-blind, randomized, placebo-controlled, Phase II study to evaluate the efficacy of AR100DP1 compared to placebo on AD lesion area(s) in subjects with mild to moderate AD.

Conditions

  • Dermatitis Atopic

Interventions

  • 0.5% AR100DP1Drug

    Investigational drug administered according to the protocol schedule.

  • PlaceboOther

    Visually identical placebo containing no active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change of IGA to 0 or 1 at visit 4 after 14 days treatmentTime frame: From Visit 2 (Day 1) to Visit 4 (Day 15) (14 days treatment)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Taipei Medical University Hospital

    Taipei, Taiwan, Taiwan · Recruiting

  • Chang Gung Memorial Hospital-Linkou

    Taoyuan, Taiwan, Taiwan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.